Currently, the core markers of AD are abnormal amyloid beta (Aβ) and tau aggregation detected by positron emission tomography (PET), as well as Aβ42 and phosphorylated tau (p-tau) levels in cerebrospinal fluid (CSF) [2]. This evidence concerns the gene MAPT and Alzheimer disease.